HRP20080406T5 - Crystalline form gamma of the chlorhydrate of ivabradine, process for its preparation and pharmaceutical composition containing it - Google Patents

Crystalline form gamma of the chlorhydrate of ivabradine, process for its preparation and pharmaceutical composition containing it

Info

Publication number: HRP20080406T5
Authority: HR; Croatia
Prior art keywords: expressed; crystalline form; ivabradine; chlorhydrate; preparation
Prior art date: 2005-02-28

Application number

HR20080406T

Other languages

English (en)

Croatian (hr)

Inventor

Horvath St�phane

Auguste Marie-Noelle

Damien G�rard

Original Assignee

Les Laboratoires Servier

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-28

Filing date

2008-08-21

Publication date

2008-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20080406(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-08-21 Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier

2008-09-30 Publication of HRP20080406T3 publication Critical patent/HRP20080406T3/xx

2008-11-30 Publication of HRP20080406T5 publication Critical patent/HRP20080406T5/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- G—PHYSICS
- G04—HOROLOGY
- G04F—TIME-INTERVAL MEASURING
- G04F1/00—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers
- G04F1/04—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity
- G04F1/06—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity by flowing-away of a prefixed quantity of fine-granular or liquid materials, e.g. sand-glass, water-clock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
- H04L51/21—Monitoring or handling of messages
- H04L51/214—Monitoring or handling of messages using selective forwarding
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
- H04L51/21—Monitoring or handling of messages
- H04L51/212—Monitoring or handling of messages using filtering or selective blocking

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Signal Processing (AREA)
Computer Networks & Wireless Communication (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Analysing Materials By The Use Of Radiation (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HR20080406T 2005-02-28 2008-08-21 Crystalline form gamma of the chlorhydrate of ivabradine, process for its preparation and pharmaceutical composition containing it HRP20080406T5 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0501989A FR2882555B1 (fr)	2005-02-28	2005-02-28	Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (2)

Publication Number	Publication Date
HRP20080406T3 HRP20080406T3 (en)	2008-09-30
HRP20080406T5 true HRP20080406T5 (en)	2008-11-30

Family

ID=34954955

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20080406T HRP20080406T5 (en)	2005-02-28	2008-08-21	Crystalline form gamma of the chlorhydrate of ivabradine, process for its preparation and pharmaceutical composition containing it

Country Status (41)

Country	Link
US (3)	US7361650B2 (de)
EP (1)	EP1707562B1 (de)
JP (1)	JP4628974B2 (de)
KR (1)	KR100835447B1 (de)
CN (1)	CN100402502C (de)
AP (1)	AP1956A (de)
AR (1)	AR052926A1 (de)
AT (1)	ATE396974T1 (de)
BR (1)	BRPI0600796B8 (de)
CA (1)	CA2537400C (de)
CO (1)	CO5770097A1 (de)
CR (1)	CR8249A (de)
CU (1)	CU23616B7 (de)
CY (1)	CY1109010T1 (de)
DE (1)	DE602006001312D1 (de)
DK (1)	DK1707562T3 (de)
EA (1)	EA008465B1 (de)
ES (1)	ES2308689T3 (de)
FR (1)	FR2882555B1 (de)
GE (1)	GEP20084467B (de)
GT (1)	GT200600088A (de)
HR (1)	HRP20080406T5 (de)
IL (1)	IL173959A0 (de)
JO (1)	JO2515B1 (de)
MA (1)	MA28134A1 (de)
ME (1)	ME02747B (de)
MY (1)	MY158129A (de)
NO (1)	NO338481B1 (de)
NZ (1)	NZ545578A (de)
PE (1)	PE20061142A1 (de)
PL (1)	PL1707562T3 (de)
PT (1)	PT1707562E (de)
RS (1)	RS50598B (de)
SA (1)	SA06270040B1 (de)
SG (1)	SG125229A1 (de)
SI (1)	SI1707562T1 (de)
TW (1)	TWI314143B (de)
UA (1)	UA86595C2 (de)
UY (1)	UY29406A1 (de)
WO (1)	WO2006092492A1 (de)
ZA (1)	ZA200601764B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2868777B1 (fr) *	2004-04-13	2006-05-26	Servier Lab	Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) *	2005-10-11	2007-12-28	Servier Lab	Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) *	2005-10-11	2007-12-28	Servier Lab	Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) *	2005-12-21	2010-12-03	Servier Lab	Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP2460797A3 (de)	2006-11-30	2012-12-05	Cadila Healthcare Limited	Verfahren zur Herstellung von Ivabradinhydrochlorid
CN101353325B (zh) *	2007-07-27	2011-11-09	上海优拓医药科技有限公司	稳定型盐酸伊伐布雷定结晶及其制备方法
EP2471780B1 (de)	2007-05-30	2014-11-26	Ind-Swift Laboratories Limited	Kristalline Ivabradinoxalatsalze und Polymorphe davon
ES2402765T3 (es)	2008-12-22	2013-05-08	Krka, D.D., Novo Mesto	Procedimiento de preparación de ivabradina
CN101774969B (zh)	2009-01-13	2012-07-04	江苏恒瑞医药股份有限公司	硫酸伊伐布雷定及其i型结晶的制备方法
WO2010128525A2 (en)	2009-05-04	2010-11-11	Dinesh Shantilal Patel	A formulation of ivabradine for treating the cardiovascular disease
SI2902384T1 (en)	2010-02-12	2018-03-30	Krka, D.D., Novo Mesto	The form of ivabradine hydrochloride
HUP1000245A2 (en)	2010-05-07	2011-11-28	Richter Gedeon Nyrt	Industrial process for the production ivabradin salts
TWI499587B (zh) *	2010-06-03	2015-09-11	Jiangsu Hengrui Medicine Co	硫酸伊伐佈雷定及其ｉ型結晶的製備方法
WO2012025940A1 (en)	2010-08-25	2012-03-01	Cadila Healthcare Limited	Polymorphic form of ivabradine hydrochloride and process for preparation thereof
EP2726462B1 (de)	2011-08-02	2017-03-22	Sandoz AG	Acetonsolvat aus ivabradinhydrochlorid
EP2773621B1 (de)	2011-11-04	2015-12-30	Synthon BV	Verfahren zur herstellung einer kristallinen delta-form von ivabradinhydrochlorid
EP2589594A1 (de)	2011-11-04	2013-05-08	Urquima S.A.	Ivabradin-Hydrochloridform IV
EP3156399A1 (de) *	2011-11-14	2017-04-19	Cadila Healthcare Limited	Polymorphe formen von ivabradinhydrochlorid
CN103183639B (zh) *	2011-12-30	2015-06-17	浙江京新药业股份有限公司	一种稳定的盐酸伊伐布雷定ii晶型及其制备方法
WO2014114341A1 (en)	2013-01-24	2014-07-31	Synthon Bv	Process for making ivabradine
ES2773502T5 (es) *	2013-03-19	2023-11-30	Chemo Res S L	Nuevo polimorfo de clorhidrato de ivabradina y método para su preparación
ITMI20130416A1 (it) *	2013-03-19	2014-09-20	Chemo Res S L	Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
CZ2013767A3 (cs)	2013-10-02	2015-04-29	Zentiva, K.S.	Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
MX363389B (es)	2013-12-12	2019-03-20	Synthon Bv	Composicion farmaceutica que comprende ivabradina amorfa.
EP2774606B1 (de)	2014-02-14	2019-01-30	Synthon B.V.	Pharmazeutische Zusammensetzung mit Ivabradin-Hydrochlorid-Polymorph IV
CZ305436B6 (cs)	2014-07-10	2015-09-16	Zentiva, K.S.	Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
US11273162B2 (en) *	2016-04-01	2022-03-15	Mississippi State University	Compositions and methods targeting HCN channels for breathing therapeutics
TR201703066A2 (tr)	2017-02-28	2018-09-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282B1 (de)	2017-02-28	2025-10-01	Sanovel Ilac Sanayi ve Ticaret A.S.	Feste orale pharmazeutische zusammensetzungen von ivabradin
US20230181472A1 (en)	2018-10-30	2023-06-15	Amgen Inc.	Process of making ivabradine hydrochloride drug product
WO2021126884A1 (en)	2019-12-16	2021-06-24	Tenax Therapeutics, Inc.	LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)
IT202000025312A1 (it)	2020-10-26	2022-04-26	Cambrex Profarmaco Milano S R L	Processi per la preparazione di polimorfi di ivabradina hcl
US20250064799A1 (en)	2021-12-31	2025-02-27	Tenax Therapeutics, Inc.	Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4490369A (en) *	1981-05-19	1984-12-25	Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung	Benzazepine derivatives, their pharmaceutical compositions and method of use
DE3119874A1 (de) *	1981-05-19	1982-12-09	Dr. Karl Thomae Gmbh, 7950 Biberach	"benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
FR2681862B1 (fr) *	1991-09-27	1993-11-12	Adir Cie	Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) *	2004-04-13	2006-05-26	Servier Lab	Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882553B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) *	2005-02-28	2007-05-04	Servier Lab	Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) *	2005-10-11	2007-12-28	Servier Lab	Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) *	2005-10-11	2007-12-28	Servier Lab	Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

2005
- 2005-02-28 FR FR0501989A patent/FR2882555B1/fr not_active Expired - Fee Related
2006
- 2006-02-13 MA MA28795A patent/MA28134A1/fr unknown
- 2006-02-14 PE PE2006000171A patent/PE20061142A1/es not_active Application Discontinuation
- 2006-02-14 JO JO200648A patent/JO2515B1/en active
- 2006-02-21 CR CR8249A patent/CR8249A/es unknown
- 2006-02-21 SG SG200601141A patent/SG125229A1/en unknown
- 2006-02-22 GT GT200600088A patent/GT200600088A/es unknown
- 2006-02-22 CU CU20060037A patent/CU23616B7/es active IP Right Grant
- 2006-02-22 AP AP2006003521A patent/AP1956A/xx active
- 2006-02-22 TW TW095105986A patent/TWI314143B/zh active
- 2006-02-22 US US11/358,955 patent/US7361650B2/en active Active
- 2006-02-24 BR BRPI0600796A patent/BRPI0600796B8/pt active IP Right Grant
- 2006-02-24 CA CA002537400A patent/CA2537400C/fr active Active
- 2006-02-24 UY UY29406A patent/UY29406A1/es not_active Application Discontinuation
- 2006-02-27 KR KR1020060018718A patent/KR100835447B1/ko active Active
- 2006-02-27 IL IL173959A patent/IL173959A0/en active IP Right Grant
- 2006-02-27 MY MYPI20060821A patent/MY158129A/en unknown
- 2006-02-27 NZ NZ545578A patent/NZ545578A/en unknown
- 2006-02-27 NO NO20060948A patent/NO338481B1/no unknown
- 2006-02-27 SA SA06270040A patent/SA06270040B1/ar unknown
- 2006-02-27 EA EA200600320A patent/EA008465B1/ru unknown
- 2006-02-27 UA UAA200602126A patent/UA86595C2/ru unknown
- 2006-02-27 GE GEAP20069265A patent/GEP20084467B/en unknown
- 2006-02-28 CO CO06019930A patent/CO5770097A1/es not_active Application Discontinuation
- 2006-02-28 AT AT06290328T patent/ATE396974T1/de active
- 2006-02-28 JP JP2006051649A patent/JP4628974B2/ja active Active
- 2006-02-28 CN CNB2006100580784A patent/CN100402502C/zh active Active
- 2006-02-28 ZA ZA200601764A patent/ZA200601764B/en unknown
- 2006-02-28 ME MEP-2008-925A patent/ME02747B/de unknown
- 2006-02-28 DE DE602006001312T patent/DE602006001312D1/de active Active
- 2006-02-28 PT PT06290328T patent/PT1707562E/pt unknown
- 2006-02-28 ES ES06290328T patent/ES2308689T3/es active Active
- 2006-02-28 PL PL06290328T patent/PL1707562T3/pl unknown
- 2006-02-28 RS RSP-2008/0365A patent/RS50598B/sr unknown
- 2006-02-28 SI SI200630042T patent/SI1707562T1/sl unknown
- 2006-02-28 AR ARP060100730A patent/AR052926A1/es not_active Application Discontinuation
- 2006-02-28 DK DK06290328T patent/DK1707562T3/da active
- 2006-02-28 WO PCT/FR2006/000443 patent/WO2006092492A1/fr not_active Ceased
- 2006-02-28 EP EP06290328A patent/EP1707562B1/de active Active
2008
- 2008-02-28 US US12/072,793 patent/US20080153803A1/en not_active Abandoned
- 2008-07-10 CY CY20081100726T patent/CY1109010T1/el unknown
- 2008-08-21 HR HR20080406T patent/HRP20080406T5/xx unknown
2009
- 2009-08-27 US US12/583,885 patent/US7867996B2/en active Active

Also Published As

Publication number	Publication date
CU23616B7 (es)	2011-01-27
NO20060948L (no)	2006-08-29
TW200640872A (en)	2006-12-01
IL173959A0 (en)	2006-07-05
UA86595C2 (ru)	2009-05-12
HRP20080406T3 (en)	2008-09-30
TWI314143B (en)	2009-09-01
ZA200601764B (en)	2007-05-30
UY29406A1 (es)	2006-07-31
BRPI0600796B8 (pt)	2021-05-25
BRPI0600796B1 (pt)	2019-02-19
US20090318417A1 (en)	2009-12-24
CO5770097A1 (es)	2007-06-29
SG125229A1 (en)	2006-09-29
EA008465B1 (ru)	2007-06-29
GEP20084467B (en)	2008-08-25
ME02747B (de)	2010-05-07
US20060194963A1 (en)	2006-08-31
KR100835447B1 (ko)	2008-06-09
US7361650B2 (en)	2008-04-22
HK1096659A1 (en)	2007-06-08
JP2006241156A (ja)	2006-09-14
PT1707562E (pt)	2008-07-08
CA2537400A1 (fr)	2006-08-28
CN100402502C (zh)	2008-07-16
CN1827602A (zh)	2006-09-06
MY158129A (en)	2016-08-30
FR2882555A1 (fr)	2006-09-01
MA28134A1 (fr)	2006-09-01
DE602006001312D1 (de)	2008-07-10
AR052926A1 (es)	2007-04-11
ATE396974T1 (de)	2008-06-15
NO338481B1 (no)	2016-08-22
EA200600320A1 (ru)	2006-08-25
AP1956A (en)	2009-02-18
JP4628974B2 (ja)	2011-02-09
DK1707562T3 (da)	2008-10-13
SI1707562T1 (sl)	2008-10-31
EP1707562B1 (de)	2008-05-28
PE20061142A1 (es)	2006-12-30
FR2882555B1 (fr)	2007-05-04
US7867996B2 (en)	2011-01-11
KR20060095499A (ko)	2006-08-31
ES2308689T3 (es)	2008-12-01
RS50598B (sr)	2010-05-07
CR8249A (es)	2008-01-21
AP2006003521A0 (en)	2006-02-28
GT200600088A (es)	2006-10-24
CU20060037A7 (es)	2008-06-30
SA06270040B1 (ar)	2010-03-23
PL1707562T3 (pl)	2008-08-29
CA2537400C (fr)	2009-12-15
NZ545578A (en)	2007-02-23
US20080153803A1 (en)	2008-06-26
WO2006092492A1 (fr)	2006-09-08
CY1109010T1 (el)	2014-07-02
JO2515B1 (en)	2010-03-17
EP1707562A1 (de)	2006-10-04
BRPI0600796A (pt)	2007-08-14
AU2006200857A1 (en)	2010-01-28

Publication	Publication Date	Title
HRP20080406T3 (en)	2008-09-30	Crystalline form gamma of the chlorhydrate of ivabradine, process for its preparation and pharmaceutical composition containing it
HRP20080417T5 (en)	2008-11-30	Crystalline form gamma-d of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it
HRP20080418T3 (en)	2008-09-30	Crystalline form beta-d of the chlorohydrate of ivabradine, process for its preparation and pharmaceutical compositions containing it
HRP20080520T3 (en)	2009-01-31	Crystalline form beta of the chlorhydrate of ivabradine, process for its preparation and pharmaceutical composition containing it
AR056573A1 (es)	2007-10-10	Forma cristalina delta del clohidrato de ivabradina,un procedimiento para su preparacion,composiciones farmaceuticas que la contienen y usos en trastornos cardiovasculares.
AR056572A1 (es)	2007-10-10	FORMA CRISTALINA ð DEL CLOHIDRATO DE IVABRADINA,UN PROCEDIMIENTO PARA SU PREPARACION,COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN Y USOS EN TRASTORNOS CARDIOVASCULARES.
TW200736199A (en)	2007-10-01	New crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it
TW200736198A (en)	2007-10-01	New crystalline form IV of agomelatine, a process for its preparation and pharmaceutical compositions containing it
MY148392A (en)	2013-04-15	Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists
ATE397605T1 (de)	2008-06-15	Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
JO3360B1 (ar)	2019-03-13	الشكل البلوري الجديد 3 للأغوميلاتين وعملية تحضيره والمكونات الصيدلانية التي تحتويه
JO2808B1 (en)	2014-09-15	Compounds and their preparation and pharmaceutical compounds
PL1831208T3 (pl)	2012-01-31	Czwartorzędowe sole amoniowe jako antagoniści M3
GEP20104964B (en)	2010-04-26	3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
TW200714598A (en)	2007-04-16	Urea derivatives, methods for their manufacture, and uses therefor
TH81392B (th)	2006-11-23	รูปแบบผลึก y ของอิวาบราดีน ไฮโดรคลอไรด์ กระบวนการสำหรับการเตรียมของสารนั้นและสารผสมทางยาซึ่งมีสารนั้น
TH81392A (de)	2006-11-23
TH89977A (th)	2008-06-10	รูปฟอร์มผลึก เดลตาd ของไอวาบราดีน ไฮโดรคลอไรด์, กระบวนการสำหรับการจัดเตรียมสารนั้นและองค์ประกอบในทางเภสัชกรรมที่มีสารนั้น
TH81393B (th)	2006-11-23	รูปแบบผลึก yd ของอิวาบราดีน ไฮโดรคลอไรด์ กระบวนการสำหรับการเตรียมของสารนั้นและสารผสมทางยาซึ่งมีสารนั้น
TH81391A (de)	2006-11-23
JO2501B1 (en)	2009-10-05	The crystalline form of gamma-D of ivabradine hydrochloride, its preparation process and its pharmaceutical ingredients
TH101955B (th)	2010-06-25	รูปที่เป็นผลึกอัลฟาของสตรอนเซียมรานีเลท, กระบวนการสำหรับเตรียมสารนี้และสารผสมทางเภสัชกรรมที่ประกอบด้วยสารนี้
TH81390A (th)	2006-11-23	รูปแบบผลึก-เบตา ของไอวาบราดีน ไฮโดรคลอไรด์ กระบวนการสำหรับการเตรียมสารนี้ และองค์ประกอบทางเภสัชกรรมซึ่งมีสารนี้อยู่